Drugs / Darusentan
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00364026 | Jun 2004 → Jul 2005 | hypertensive disorder | Gilead Sciences | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00389675 | May 2007 → Feb 2010 | hypertensive disorder | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT00389779 | Sep 2006 → Aug 2009 | hypertensive disorder | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00353574 | Sep 2006 → Feb 2010 | hypertensive disorder | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT00330369 | Jun 2006 → Jan 2009 | hypertensive disorder | Gilead Sciences | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00738049 Comparator | Jun 2009 → Aug 2011 | coronary atherosclerosis | K.Lance Gould | Completed | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-12-14 | Gilead Sciences | Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpoints gilead.com ↗ |
| 2009-09-13 | Gilead Sciences | Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet gilead.com ↗ |
| 2009-05-08 | Gilead Sciences | Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients gilead.com ↗ |
| 2009-04-13 | Gilead Sciences | Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009 gilead.com ↗ |
| 2009-04-02 | Gilead Sciences | Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints gilead.com ↗ |
| 2007-09-24 | Gilead Sciences | Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Published in Journal of Clinical Hypertension gilead.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darusentan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00389675 ↗ |
| Known as | HMR-4005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23261 ↗ |
| Known as | LU-135252 | ChEMBL registry synonym — accepted as the source's own label CHEMBL23261 ↗ |
| Action | Inhibit | “selective endothelin type A antagonist” PMID 19748665 ↗ Sep 20092“Endothelin receptor ET-A antagonist” CHEMBL23261 ↗ “Endothelin receptor ET-B antagonist” CHEMBL23261 ↗ |
| Modality | Other / unclassified | “the new vasodilatory, selective endothelin type A antagonist, darusentan” PMID 19748665 ↗ Sep 2009 |
| Route | Oral | “Darusentan administered orally once daily” NCT00330369 ↗ |
| Target | EDNRA | “Endothelin receptor ET-A antagonist” CHEMBL23261 ↗ |
| Target | EDNRB | “Endothelin receptor ET-B antagonist” CHEMBL23261 ↗ |